Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02117739 · ClinicalTrials.gov registry record · Phase 1

Photoallergy Potential of Dapsone Gel in Healthy Volunteers

A Phase 1 study of Healthy Volunteers, sponsored by Almirall, S.A..

Completed
Registry status
Phase 1
Development phase
58
Enrollment target
1
Study location

NCT02117739 is a Phase 1 study of Healthy Volunteers that has completed, run by Almirall, S.A.. The registered enrollment target is 58 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02117739, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Almirall, S.A..

COMPLETED
Registry status
Phase 1
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the potential of dapsone gel and its vehicle to cause a photoallergic reaction after repeated application and irradiation to the skin of healthy volunteers under controlled conditions.

Conditions Studied

Interventions

  • DRUG dapsone gel
  • DRUG dapsone gel vehicle

Study Locations (1)

New Jersey

  • - Fair Lawn

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2014-04
Est. Completion 2014-07
Phase Phase 1

Sponsor

Almirall, S.A.

19 total trials

What the Registry Record Tells You About NCT02117739

The ClinicalTrials.gov registry entry for NCT02117739 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which dapsone gel is the first listed.

NCT02117739 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT02117739 about?

NCT02117739 is a clinical study titled "Photoallergy Potential of Dapsone Gel in Healthy Volunteers". This study will evaluate the potential of dapsone gel and its vehicle to cause a photoallergic reaction after repeated application and irradiation to the skin of healthy volunteers under controlled conditions.

What is the current status of trial NCT02117739?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2014-04. Estimated completion is 2014-07.

What conditions does trial NCT02117739 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT02117739?

The interventions under investigation include: dapsone gel (DRUG), dapsone gel vehicle (DRUG).

Who is sponsoring clinical trial NCT02117739?

This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02117739 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.